指南与共识乳腺外科

St Gallen 2019指南可能低估小叶乳腺癌腋窝分期:一项基于人群的研究

St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study.
指南 / 共识 · Br J Surg · 2021-01-01

该研究基于瑞典国家乳腺癌登记库2014–2017年数据,纳入符合St Gallen 2019豁免完成性腋窝淋巴结清扫(cALND)标准的1886例患者(小叶癌329例,非特殊型浸润性导管癌1507例)。小叶癌患者≥4枚腋窝淋巴结转移的患病率(31.0%)高于非特殊型(14.9%),调整OR为2.26(95%CI 1.59–3.21);在luminal A样亚型中,小叶癌≥4枚淋巴结转移的比例为18.5%(52/281),非特殊型为3.3%(43/1299)(P<0.001)。结论提示,对luminal A样小叶癌伴1–2枚前哨淋巴结转移者豁免cALND可能导致约五分之一患者分期不足和治疗不足。

要点

  • 小叶癌伴1–2枚前哨淋巴结转移者豁免cALND后,约五分之一存在≥4枚腋窝淋巴结转移。
  • 小叶癌≥4枚腋窝淋巴结转移的调整OR为2.26(95%CI 1.59–3.21),高于非特殊型。
  • luminal A样小叶癌中≥4枚淋巴结转移占18.5%,显著高于非特殊型的3.3%。

核心结论

  • 小叶癌患者更常见luminal A样且伴≥4枚淋巴结转移,豁免cALND存在分期不足和治疗不足风险。

研究设计与样本

  • 基于瑞典国家乳腺癌登记库的人群队列研究,纳入2014–2017年手术且符合St Gallen 2019豁免cALND标准的患者1886例(小叶癌329例,非特殊型1507例)。

主要发现

  • 小叶癌≥4枚腋窝淋巴结转移的患病率为31.0%,非特殊型为14.9%,调整OR为2.26(95%CI 1.59–3.21)。
  • luminal A样亚型中,小叶癌≥4枚淋巴结转移为52/281(18.5%),非特殊型为43/1299(3.3%)(P<0.001)。

关键数值与推荐

  • St Gallen 2019指南推荐:无论组织学类型,1–2枚前哨淋巴结转移者豁免cALND。
  • St Gallen 2019指南推荐:luminal A样且≥4枚腋窝淋巴结转移者接受辅助化疗。

临床怎么用

  • 对luminal A样小叶癌伴1–2枚前哨淋巴结转移者,豁免cALND前应关注腋窝分期不足风险。
  • 若豁免cALND,需综合评估辅助化疗指征,避免因分期不足导致治疗不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The St Gallen 2019 guidelines for primary therapy of early breast cancer recommend omission of completion axillary lymph node dissection (cALND), regardless of histological type, in patients with one or two sentinel lymph node (SLN) metastases. Concurrently, adjuvant chemotherapy is endorsed for luminal A-like disease with four or more axillary lymph node (ALN) metastases. The aim of this study was to estimate the proportion of patients with invasive lobular cancer (ILC) versus invasive ductal cancer of no special type (NST) with one or two SLN metastases for whom cALND would have led to a recommendation for adjuvant chemotherapy. METHODS: Patients with ILC and NST who had surgery between 2014 and 2017 were identified in the National Breast Cancer Register of Sweden. After exclusion of patients with incongruent or missing data, those who fulfilled the St Gallen 2019 criteria for cALND omission were included in the population-based study cohort. RESULTS: Some 1886 patients in total were included in the study, 329 with ILC and 1507 with NST. Patients with ILC had a higher metastatic nodal burden and were more likely to have a luminal A-like subtype than those with NST. The prevalence of at least four ALN metastases was higher in ILC (31.0 per cent) than NST (14.9 per cent), corresponding to an adjusted odds ratio of 2.26 (95 per cent c.i. 1.59 to 3.21). Luminal A-like breast cancers with four or more ALN metastases were over-represented in ILC compared with NST, 52 of 281 (18.5 per cent) versus 43 of 1299 (3.3 per cent) (P < 0.001). CONCLUSION: Patients with ILC more often have luminal A-like breast cancer with at least four nodal metastases. Omission of cALND in patients with luminal A-like invasive lobular cancer and one or two SLN metastases warrants future attention as there is a risk of nodal understaging and undertreatment in one-fifth of patients. Nowadays patients who have breast cancer with one to two metastases in the first draining axillary lymph nodes are not recommended to undergo completion surgery of the axilla if they have breast-conserving surgery and will have adequate postoperative oncological treatment. Lobular breast cancer is the second most common type of breast cancer, and this study shows that patients with this type have an increased risk of having lymph node metastases remaining if completion surgery is omitted. The diagnosis of additional lymph node metastases is importance for guidance regarding adjuvant oncological therapy in lobular cancer with a hormonally sensitive low proliferative subtype.

来源:Br J Surg,查看原文。版权归原作者所有。

引用

  1. Narbe U, Bendahl PO, Fernö M, et al. St Gallen 2019 guidelines understage the axilla in lobular breast cancer: a population-based study. Br J Surg. 2021. PMID: 34636842. doi:10.1093/bjs/znab327

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。